Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Tenofovir Disoproxil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 2/20 | 0.94 |
| ▸ | CYP3A4 | P08684 | 14/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 14/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tenofovir Disoproxil SCHEMBL1560984 | 1.00 | FAP (0.94) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL3234290 | 0.97 | FAP (1.00) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL16237284 | 0.97 | FAP (1.00) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL2670560 | 0.97 | FAP (1.00) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL343783 | 0.97 | FAP (1.00) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL18190782 | 0.97 | FAP (1.00) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL40021 | 0.97 | FAP (1.00) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL985120 | 0.97 | FAP (1.00) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL29356301 | 0.97 | FAP (1.00) | FAPCYP3A4CYP2D6 | |
| Tenofovir Disoproxil SCHEMBL22157305 | 0.95 | FAP (0.93) | FAPCYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11311505-B2 | Synergistic compositions to stimulate the synthesis of human lung and sinus surfactants to decrease coughing, increase FEV-1/FVC ratios, decrease lung fibrosis, by increasing apoptosis of myofibroblasts | CELLULAR SCIENCES, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2021040673-A1 | METHODS FOR THE TREATMENT OF CHRONIC HYPOXEMIA AND INHIBITING LUNG FIBROSIS IN PATIENTS WITH PULMONARY FIBROSIS WITH AND WITHOUT COPD | MARTIN ALAIN (US) | 2021-03-04 | — | — | WO | disclosed |
| WO-2021034298-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF CHRONIC HYPOXEMIA AND DYSPNEA | MARTIN ALAIN (US) | 2021-02-25 | — | — | WO | disclosed |
| US-10813893-B2 | Compositions and methods for the treatment and prevention of chronic hypoxemia and dyspnea | CELLULAR SCIENCES, INC. (US) | 2020-10-27 | — | — | US | disclosed |
| US-20200237815-A1 | Methods for treatment of lung damage and for inhibition of lung fibrosis | MARTIN ALAIN (US) | 2020-07-30 | — | — | US | disclosed |
| CN-110302206-A | Application of the tenofovir tenofovir disoproxil fumarate in the drug that preparation inhibits toxoplasma growth | 山东大学 | 2019-10-08 | — | — | CN | disclosed |
| US-20180243246-A1 | Compositions and Methods for the Treatment and Prevention of Chronic Hypoxemia and Dyspnea. | CELLULAR SCIENCES, INC. | 2018-08-30 | — | — | US | disclosed |
| CN-105820188-A | Medicinal preparation containing tenofovir disoproxil fumarate (vitamin E), and use thereof | 刘天军 | 2016-08-03 | — | — | CN | disclosed |
| EP-2922572-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | AB Science (FR) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014079709-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | AB SCIENCE (FR) | 2014-05-30 | — | — | WO | disclosed |
| US-7772197-B2 | 1,3,5-triazines for treatment of viral diseases | 1,3,5-Triazines for Treatment of Viral Diseases (US) | 2010-08-10 | — | — | US | disclosed |
| US-7642247-B2 | 1,3,5-triazines for treatment of viral diseases | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2010-01-05 | — | — | US | disclosed |
| US-20070207973-A1 | 1,3,5-Triazines for Treatment of Viral Diseases | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2007-09-06 | — | — | US | disclosed |
| US-20070142310-A1 | 1,3,5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1778251-A2 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES, INC. (US) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006110157-A2 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
| EP-1545558-A2 | 1, 3, 5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | Koronis Pharmaceuticals, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040127436-A1 | 1,3,5-Triazines for treatment of viral diseases | KORONIS PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| WO-2004028454-A2 | 1, 3, 5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | KORONIS PHARMACEUTICALS, INCORPORATED (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207973-A1 | 1,3,5-Triazines for Treatment of Viral Diseases | HAVCR2, EIF2AK2, IKZF3 | FAP 2054/4885CYP3A4 2199/4885CYP2D6 3769/4885 |
| US-20070142310-A1 | 1,3,5-TRIAZINES FOR TREATMENT OF VIRAL DISEASES | HAVCR2, EIF2AK2, IKZF3 | FAP 2054/4885CYP3A4 2199/4885CYP2D6 3769/4885 |
| US-20040127436-A1 | 1,3,5-Triazines for treatment of viral diseases | HAVCR2, EIF2AK2, IKZF3 | FAP 2054/4885CYP3A4 2199/4885CYP2D6 3769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.